KCNV2 CRISPR/Cas9 gene therapy (Queen Mary University of London/MeiraGTx)

N/A

Report date: 2025/01/26 18:19:21

Base Information

Drug NameKCNV2 CRISPR/Cas9 gene therapy (Queen Mary University of London/MeiraGTx)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionPotassium voltage-gated channel subfamily V member 2 gene transference
TargetsPotassium voltage-gated channel subfamily V member 2
Therapy Area/IndicationsCone Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesQueen Mary University Of London
China Registration ClassN/A

Develop Information

Active CompaniesQueen Mary University Of LondonMeiragtx Uk Ii Ltd
Inactive CompaniesN/A
Active IndicationsCone Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A